Monopar Therapeutics Inc
NASDAQ:MNPR

Watchlist Manager
Monopar Therapeutics Inc Logo
Monopar Therapeutics Inc
NASDAQ:MNPR
Watchlist
Price: 25.82 USD 8.53% Market Closed
Market Cap: 136.3m USD
Have any thoughts about
Monopar Therapeutics Inc?
Write Note

Monopar Therapeutics Inc
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Monopar Therapeutics Inc
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Monopar Therapeutics Inc
NASDAQ:MNPR
Cash from Operating Activities
-$6m
CAGR 3-Years
3%
CAGR 5-Years
-16%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Cash from Operating Activities
$16.5B
CAGR 3-Years
-10%
CAGR 5-Years
4%
CAGR 10-Years
12%
Gilead Sciences Inc
NASDAQ:GILD
Cash from Operating Activities
$10B
CAGR 3-Years
0%
CAGR 5-Years
2%
CAGR 10-Years
0%
Amgen Inc
NASDAQ:AMGN
Cash from Operating Activities
$7.3B
CAGR 3-Years
-6%
CAGR 5-Years
-6%
CAGR 10-Years
-1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash from Operating Activities
-$842.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-9%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash from Operating Activities
$4.2B
CAGR 3-Years
-11%
CAGR 5-Years
12%
CAGR 10-Years
18%
No Stocks Found

Monopar Therapeutics Inc
Glance View

Market Cap
136.3m USD
Industry
Biotechnology

Monopar Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. The company is headquartered in Wilmette, Illinois and currently employs 9 full-time employees. The company went IPO on 2019-12-19. The firm is primarily focused on developing therapeutics designed for cancer patients. Its product pipeline includes Validive, camsirubicin, MNPR-101, and MNPR-202. The Validive is a first-in-class mucoadhesive buccal tablet for the prevention of radiation induced severe oral mucositis (SOM) in oropharyngeal cancer patients. Its camsirubicin is a clinical stage topoisomerase II-alpha selective novel analog of doxorubicin engineered specifically to retain anticancer activity while minimizing toxic effects on the heart. Its MNPR-101 is a humanized monoclonal antibody designed to bind a specific cell surface receptor found on cancer cells, the urokinase plasminogen activator receptor (uPAR), and to interrupt several pathways required for tumor growth and progression. The MNPR-202 is an early stage camsirubicin analog for various cancers.

MNPR Intrinsic Value
18.25 USD
Overvaluation 29%
Intrinsic Value
Price

See Also

What is Monopar Therapeutics Inc's Cash from Operating Activities?
Cash from Operating Activities
-6m USD

Based on the financial report for Sep 30, 2024, Monopar Therapeutics Inc's Cash from Operating Activities amounts to -6m USD.

What is Monopar Therapeutics Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-16%

Over the last year, the Cash from Operating Activities growth was 22%. The average annual Cash from Operating Activities growth rates for Monopar Therapeutics Inc have been 3% over the past three years , -16% over the past five years .

Back to Top